



STATE OF ARKANSAS  
**Department of Finance  
and Administration**

**C**  
**OFFICE OF BUDGET**  
1509 West Seventh Street, Suite 402  
Post Office Box 3278  
Little Rock, Arkansas 72203-3278  
Phone: (501) 682-1941  
Fax: (501) 682-1086  
www.arkansas.gov/dfa

January 2, 2026

Senator Jonathan Dismang, Co-Chair  
Representative Jeffrey Wardlaw, Co-Chair  
Performance Evaluation & Expenditure Review Committee  
Arkansas Legislative Council  
State Capitol Building  
Little Rock, AR 72201

RE: FY 26 American Rescue Plan Act Request

Dear Co-Chairs:

Pursuant to Section 35 (01) of Act 1006 of 2025, I am forwarding the attached American Rescue Plan Act request(s) that have received my approval as Chief Fiscal Officer of the State.

1. Department of Health – Division of Health – Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases – Returning Excess/Unused Funds to the CDC \$1

Sincerely,

A handwritten signature in black ink, appearing to read 'JL Hudson', written over a white background.

James L. Hudson  
Secretary

Attachment(s)

**AMERICAN RESCUE PLAN ACT OF 2021 PROGRAM APPROPRIATION  
AND PERSONNEL AUTHORIZATION REQUEST  
SECTION 35 OF ACT 1006 OF 2025**

Agency: Arkansas Department of Health Business Area Code: 0645

Program Title: Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases

Granting Organization: Centers for Disease Control and Prevention (CDC) CFDA #: 93.323

Effective Date of Authorization: Beginning: 7/1/2025 Ending: 6/30/2026

Purpose of Grant / Reason for addition or change (include attachments as necessary to provide thorough information):

**ADH is requesting appropriation needed to return excess / unused funds to CDC.**

**American Rescue Plan Act Program Funding**

Func. Area: HHS  
Funds Center: AZ3

Fund Code: FRP645V  
Internal Order/WBS Element: RCAOCF21

Direct Funding: X  
State: \_\_\_\_\_  
Continuation: \_\_\_\_\_

	Program Funding Amount
Regular Salaries	
Extra Help	
Personal Services Matching	
Operating Expenses	1
Conference & Travel Expenses	
Professional Fees	
Capital Outlay	
Data Processing	
Grants and Aid (CI: 04)	
Other:	
Other:	
<b>Total</b>	\$ 1

Anticipated Duration of Federal Funds: 07/31/2024

<b>State Technology Plan Approval</b>	<b>Date</b>
Items requested for information technology must be in compliance with Technology Plans as submitted.	

**Positions to be established: (list each position separately)**

\* unclassified positions only

Org Unit	Pers Area	Pers SubArea	Cost Center	Position Number	Comnt Item	Position Title	Class Code	Grade	Line Item Maximum *

**State funds will not be used to replace federal funds when such funds expire, unless appropriated by the General Assembly and authorized by the Governor.**

Approved by: [Signature] 12-5-25  
Cabinet Secretary/Agency Director Date

Cayce Raney 12/31/25  
Office of Budget Date

Office of Personnel Mgmt Date



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award

Award# 6 NU50CK000538-03-01

FAIN# NU50CK000538

Federal Award Date: 08/05/2021

<b>Recipient Information</b>	
<b>1. Recipient Name</b>	
Arkansas Department of Health 4815 W Markham St Center for Public Health Pract Little Rock, AR 72205-3866 [No Phone Record]	
<b>2. Congressional District of Recipient</b>	
02	
<b>3. Payment System Identifier (ID)</b>	
1716007358A1	
<b>4. Employer Identification Number (EIN)</b>	
710847443	
<b>5. Data Universal Numbering System (DUNS)</b>	
809873185	
<b>6. Recipient's Unique Entity Identifier</b>	
<b>7. Project Director or Principal Investigator</b>	
Mr, Michael Cima Ph.D. Michael.Cima@Arkansas.gov 501-683-6596	
<b>8. Authorized Official</b>	
Ms. Jo Thompson Chief Financial Officer Jo.C.Thompson@arkansas.gov (501) 280-4157	
<b>Federal Agency Information</b>	
CDC Office of Financial Resources	
<b>9. Awarding Agency Contact Information</b>	
Kim McDowell Grant Management Specialist qpx9@cdc.gov 404-498-4105	
<b>10. Program Official Contact Information</b>	
Ms. Jennifer Simmons Public Health Advisor Ext0@cdc.gov 404.718.4579	

<b>Federal Award Information</b>	
<b>11. Award Number</b>	
6 NU50CK000538-03-01	
<b>12. Unique Federal Award Identification Number (FAIN)</b>	
NU50CK000538	
<b>13. Statutory Authority</b>	
301(A)AND317(K)(2)FHS42USC241(A)247B(K)2	
<b>14. Federal Award Project Title</b>	
CK19-1904 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC)	
<b>15. Assistance Listing Number</b>	
93,323	
<b>16. Assistance Listing Program Title</b>	
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	
<b>17. Award Action Type</b>	
Supplement	
<b>18. Is the Award R&amp;D?</b>	
No	

<b>Summary Federal Award Financial Information</b>		
<b>19. Budget Period Start Date</b>	08/01/2021	<b>- End Date</b> 07/31/2022
<b>20. Total Amount of Federal Funds Obligated by this Action</b>		\$12,348,061.00
20a. Direct Cost Amount		\$12,329,594.00
20b. Indirect Cost Amount		\$18,467.00
<b>21. Authorized Carryover</b>		\$0.00
<b>22. Offset</b>		\$0.00
<b>23. Total Amount of Federal Funds Obligated this budget period</b>		\$1,251,317.00
<b>24. Total Approved Cost Sharing or Matching, where applicable</b>		\$0.00
<b>25. Total Federal and Non-Federal Approved this Budget Period</b>		\$13,599,378.00
<b>26. Project Period Start Date</b>	08/01/2019	<b>- End Date</b> 07/31/2024
<b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b>		Not Available

<b>28. Authorized Treatment of Program Income</b>
ADDITIONAL COSTS
<b>29. Grants Management Officer - Signature</b>
Ms. Freda Johnson Grants Management Officer

<b>30. Remarks</b>
--------------------



DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Centers for Disease Control and Prevention

Notice of Award

Award# 6 NU50CK000538-03-01  
FAIN# NU50CK000538  
Federal Award Date: 08/05/2021

<b>Recipient Information</b>	
<b>Recipient Name</b>	
Arkansas Department of Health 4815 W Markham St Center for Public Health Pract Little Rock, AR 72205-3866 [No Phone Record]	
<b>Congressional District of Recipient</b>	
02	
<b>Payment Account Number and Type</b>	
1716007358A1	
<b>Employer Identification Number (EIN) Data</b>	
710847443	
<b>Universal Numbering System (DUNS)</b>	
809873185	
<b>Recipient's Unique Entity Identifier</b>	
Not Available	
<b>31. Assistance Type</b>	
Cooperative Agreement	
<b>32. Type of Award</b>	
Demonstration	

<b>33. Approved Budget (Excludes Direct Assistance)</b>	
I. Financial Assistance from the Federal Awarding Agency Only	
II. Total project costs including grant funds and all other financial participation	
a. Salaries and Wages	\$449,883.00
b. Fringe Benefits	\$159,171.00
c. Total Personnel Costs	\$609,054.00
d. Equipment	\$0.00
e. Supplies	\$153,580.00
f. Travel	\$58,472.00
g. Construction	\$0.00
h. Other	\$12,299,199.00
i. Contractual	\$349,000.00
<b>j. TOTAL DIRECT COSTS</b>	<b>\$13,469,305.00</b>
<b>k. INDIRECT COSTS</b>	<b>\$130,073.00</b>
<b>L. TOTAL APPROVED BUDGET</b>	<b>\$13,599,378.00</b>
m. Federal Share	\$13,599,378.00
n. Non-Federal Share	\$0.00

<b>34. Accounting Classification Codes</b>						
FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION	FINANCIAL ASSISTANCE	APPROPRIATION
1-9210400	19NU50CK000538	CK	41.51		\$109,887.00	75-21-0959
1-9390EWQ	19NU50CK000538DMODC3	CK	41.51		\$1,953,568.00	75-2024-0943
1-9390F3H	19NU50CK000538DMODC3	CK	41.51		\$975,606.00	75-2024-0943
1-9390I9L	19NU50CK000538DOJC6	CK	41.51		\$9,310,000.00	75-X-0140



**DEPARTMENT OF HEALTH AND HUMAN SERVICES** Notice of Award

Centers for Disease Control and Prevention

Award# 6 NU50CK000538-03-01

FAIN# NU50CK000538

Federal Award Date: 08/05/2021

**Direct Assistance**

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

## AWARD ATTACHMENTS

Arkansas Department of Health

6 NU50CK000538-03-01

---

1. Terms and Conditions Data Mitigation

**ADDITIONAL AWARD INFORMATION**

**Incorporation:** In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CK19-1904, titled *Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases(ELC)*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NOA).

**Supplemental Funding:** Additional funding in the amount \$12,348,061 is approved for the Year 03 budget period, which is August 1, 2021 through July 31, 2022. The availability of funds is shown below.

COVID Funded Component	Amount	End of Funding Availability	Suffix Document Number in PMS
Data Modernization	\$2,928,174	July 31, 2023	DMODC3
Detection & Mitigation of COVID in Confinement Facilities	\$9,310,000	July 31, 2024	DOJC6
Core	\$109,887	July 31, 2022	None

**Coronavirus Disease 2019 (COVID-19) Funds:** A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); the Consolidated Appropriations Act and the Coronavirus Response and Relief Supplement Appropriations Act, 2021 (P.L. 116-260) and/or the American Rescue Plan of 2021 [P.L. 117-2] agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

To achieve the public health objectives of ensuring the health, safety, and welfare of all Americans, Recipient must distribute or administer vaccine without discriminating on non-public-health grounds within a prioritized group.

**Unallowable Costs:**

1. Research
2. Clinical care
3. Construction
4. Publicity and propaganda (lobbying);
5. Other than for normal and recognized executive-legislative relationships, no funds may be used for:
  - a. publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
  - b. the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
  - c. See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:  
[https://www.cdc.gov/grants/documents/AntiLobbying\\_Restrictions\\_for\\_CDC\\_Grantees\\_July\\_2012.pdf](https://www.cdc.gov/grants/documents/AntiLobbying_Restrictions_for_CDC_Grantees_July_2012.pdf)
6. All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

**COVID-19 Funding Budget Revision Requirement:** The recipient must submit a revised budget with a narrative justification, using the ELC budget workbook provided in the Grant Note associated with this award, within 90 days of receipt of the Notice of Award. Submission must be made as a budget revision amendment and not as a Grant Note. If the date falls on a weekend or holiday, the submission will be due the following business day. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Awarding Agency Contact Information section on the first page before the due date.

**REPORTING REQUIREMENTS**



**Reporting:** Please reference the applicable guidance for reporting requirements related to Data Modernization and Detection & Mitigation of COVID in Confinement Facilities activities.

**Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIS):** Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services  
Kim McDowell, Grants Management Specialist  
Centers for Disease Control and Prevention  
Branch 1  
2939 Flowers Road, MS-TV-2 Atlanta, GA 30341  
Email:qpx9@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

**AND**

U.S. Department of Health and Human Services Office of the Inspector General  
ATTN: Mandatory Grant Disclosures, Intake Coordinator 3301 Independence Avenue, SW  
Cohen Building, Room 5527 Washington, DC 20201  
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or Email:  
[MandatoryGranteeDisclosures@oig.hhs.gov](mailto:MandatoryGranteeDisclosures@oig.hhs.gov)

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

#### **PAYMENT INFORMATION**

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to [hhstips@oig.hhs.gov](mailto:hhstips@oig.hhs.gov) or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC

*20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.*

**Payment Management System Subaccount:** Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of **Page 2** of the Notice of Award must be known to draw down funds.

**Stewardship:** The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

Title: Detection & Mitigation of COVID-19 in Confinement Facilities

Funding Period: August 1<sup>st</sup>, 2021 – July 31, 2024 \*Note award was approved in April 2022 **Previous Grant Award was CARES Act (Not ARP)**

Funding Amount: \$9,310,000

Executive Summary:

The Arkansas Department of Health (ADH) has received federal funding from the Centers for Disease Control and Prevention (CDC), in collaboration with the Department of Justice, through the Epidemiology and Laboratory Capacity (ELC) Cooperative Agreement to support detection and mitigation of COVID-19 in confinement facilities. Specifically, the funding is intended to provide testing and infection control resources to our State's prisons and jails to identify cases rapidly and mitigate the spread of COVID-19 within these settings.

The ADH plans to utilize funds to directly support prisons and jails in the following ways: 1) provide funding directly to the Arkansas Department of Corrections through a memorandum of agreement (MOA) to support a variety of response activities (outlined below) based on the need of each individual facility; 2) solicit a subgrant for funds to be dispersed to city and county jails to support a variety of response activities (outlined below) based on the need of each individual facility; 3) purchase laboratory supplies for COVID-19 testing at the Arkansas State Public Health Laboratory; 4) purchase point of care testing materials to be distributed to prisons and jails; 5) solicit a professional services agreement to provide strike teams for collection and delivery of samples to the SPHL for testing; and 6) a small, dedicated staff to COVID-19 mitigation in confined settings at the Arkansas Department of Health.

These funds are to be used for a variety of response activities, determined by need, to detect and mitigate the COVID-19 pandemic. The ADH is required to ensure that funds are utilized to conduct the single required activity and can choose among optional activities to support response activities. ADH will guide prisons and jails on ensuring that funds are utilized within these parameters. Funds cannot be used to provide clinical services, general staffing, or purchase, storage, or administer vaccines. Allowable activities are as follows:

a. Required Activity:

1. Establish and implement diagnostic and screening testing programs for detainees/inmates, staff, and visitors. \*Note: Laboratory diagnostic funds are available to be spent at the State Public Health Laboratory.

b. Optional Activities:

1. Conduct COVID-19 testing and contact tracing.
2. Implement recommended isolation and quarantine strategies including for confirmed and suspected cases and close contacts.
3. Implement distancing policies and training staff on maintaining distancing practices.
4. Develop staffing strategies that reduce the risk of virus transmission (e.g. organize staff assignments so that the same staff are assigned to the same areas of the facility over time).
5. Implement policies and practices that support transportation that are consistent with recommendations to reduce transmission.
6. Implement visitor policies consistent with recommendations to reduce virus risk.
7. Implement infection control practices inside facilities.

8. Develop and implement procedures and systems to improve confinement facility preparedness and response efforts.
9. Coordinate preparedness and response efforts with state, local, tribal, and territorial public health departments to prevent, prepare for, and respond to COVID-19 within confinement facilities.
10. Enhance and/or improve the practices of confinement facilities to mitigate the spread of COVID-19, and to reduce the risk of virus transmission and exposure to environmental health hazards.
11. Purchase of additional supplies to sanitize and clean the confinement facilities. Funding must not supplant existing expenditures on such supplies and can only be used to support enhanced cleaning efforts.
12. Educate and train confinement facility staff and residents/detainees/inmates on sanitation and minimizing the spread of infectious diseases.
13. Implement COVID-19 mitigation practices to minimize potential opportunities for exposure including video conferencing technology and other measures for attorney/client purposes, court appearances, family visiting, and programming.